Two former GOP health care lawmakers are warning the White House that rising infectious disease rates coupled with the administration’s mixed messaging on vaccines are a “self-inflicted wound” that ...

FDA published long-awaited final guidance Monday (Oct. 19) laying out what identity and safety information manufacturers and distributors should include in a new dietary ingredient notification (NDIN) ...

A bipartisan group of 22 state attorneys general is filing a notice in bankruptcy proceedings for Character Technologies, Inc., the firm behind the chatbot company Character.AI that presented AI ...

Health policy stakeholders and former FDA officials are backing a group of bipartisan drug development reforms they say could boost domestic clinical research and expand patient access to treatments, ...

FDA has formally asked the White House Office of Management and Budget (OMB) to approve an “interim access policy” that could create a temporary pathway for state-licensed pharmacies to compound ...

HHS’ planning office is backing major cuts to hospitals’ 340B reimbursement rates, arguing lower payments would better reflect acquisition costs and discourage hospitals from profiting from the ...

FDA on Wednesday (Oct. 14) launched a Rare Disease Framework Initiative that it says will reform the development of rare disease treatments by considering each disease’s specific patient population ...

The lobby representing agents and brokers has asked a federal court to block the administration’s move to slap a moratorium on new agents/brokers ahead of the 2027 Affordable Care Act open enrollment ...

Glucose monitoring device company Dexcom is trying to quell a firestorm on social media after telling patients to leave the app unless they agree to the company’s new terms that adjust provisions on ...

A new group of hospitals is rallying for the United States District Court for the District of Maine to once again block the government from implementing a pilot program that will replace upfront ...

AMA released a framework to govern agentic artificial intelligence tools used in clinical settings, asserting that AI's clinical authority must be proven through adequate evidence that is continuously ...

An advocacy group that previously filed a citizen’s petition urging FDA to reevaluate drug development standards is now asking that the upcoming PDUFA reauthorization reflect the agency’s new rare ...